Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic.

MLA

Tavallai, Mehrad, et al. “Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic.” Frontiers in Oncology, June 2016, pp. 1–19. EBSCOhost, https://doi.org/10.3389/fonc.2016.00142.

APA

Tavallai, M., Booth, L., Roberts, J. L., Poklepovic, A., & Dent, P. (2016). Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic. Frontiers in Oncology, 1–19. https://doi.org/10.3389/fonc.2016.00142

Chicago

Tavallai, Mehrad, Laurence Booth, Jane L. Roberts, Andrew Poklepovic, and Paul Dent. 2016. “Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic.” Frontiers in Oncology, June, 1–19. doi:10.3389/fonc.2016.00142.